VREOFOTCPharmaceutical PreparationsFiscal year ends December 31

Vireo Growth Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$9.01+0.01 (+0.11%)

Close on Oct 19, 2026

Market cap: $406.23M
P/E (TTM): –
Dividend yield: –

Vireo Growth Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	269	99	88	75	54	49
Cost of Revenue	–	–	–	39	32	31
Gross Profit	127	51	44	31	20	17
Selling, General & Admin	81	28	28	34	34	26
Advertising Expenses	–	0.86	0.79	1.07	–	–
Operating Expenses	128	37	34	38	40	40
Operating Income	-1.05	14	11	-6.94	-20	-23
Interest Expense	–	31	31	23	11	5.10
Other Non-Operating Income	-39	-30	-28	-30	-9.09	8.89
Asset Impairment Charges	0	–	0.41	8.60	5.17	0
Gain (Loss) on Sale of Assets	–	–	-2.91	0.17	6.90	-0.01
Pretax Income	-40	-17	-18	-37	-30	-14
Income Tax Expense	28	11	7.72	5.89	4.12	8.79
Net Income incl. Noncontrolling Interests	-68	-28	-26	-42	-34	-23
Net Income	-68	-28	-26	-42	-34	-23
EPS (Basic)(per share)	-2.70	-4.80	-5.70	-9.90	-8.10	-7.20
EPS (Diluted)(per share)	-2.70	-4.80	-5.70	-9.90	-8.10	-7.20
Shares Outstanding (Basic, Weighted)(shares)	24	6.01	4.51	4.27	4.13	3.25
Shares Outstanding (Diluted, Weighted)(shares)	24	6.01	4.51	4.27	4.13	3.25
EBITDA	15	16	13	-3.60	-17	-21

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 48.6%
Operating margin: 0.3%
Net margin: -13.1%
Return on equity, FY2025: -37.5%

Financial strength

Current ratio: 1.01
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 26.4%

Valuation

P/E ratio: –
Price to sales: 0.79
Price to book: 0.92
Dividend yield: –